Research programme: temozolomide/thalidomide nanoparticles - Pharmaco-Kinesis

Drug Profile

Research programme: temozolomide/thalidomide nanoparticles - Pharmaco-Kinesis

Alternative Names: Temozolomide/thalidomide; Thalidomide/temozolomide

Latest Information Update: 02 Jul 2015

Price : $50

At a glance

  • Originator Pharmaco-Kinesis Corporation
  • Class Imidazoles; Phthalimides; Piperidones; Small molecules; Triazenes
  • Mechanism of Action Alkylating agents; Angiogenesis inhibitors; DNA cross linking agents; DNA synthesis inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Glioma

Most Recent Events

  • 26 May 2015 Preclinical trials in Glioma in USA (Parenteral)
  • 30 Apr 2013 Early research in Glioma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top